V. Tagarielli

SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience

M. Copetti, A. Mangia, G. Lauletta, 2019, PloS one.

High SVR rates in patients with and without cirrhosis treated in real life with Sofosbuvir/Velpatasvir (SOF/VEL) combination for 12 weeks without Ribavirin (RBV)

A. Mangia, G. Lauletta, D. Potenza, 2018 .